Skip to content

Conserved epitope-driven in silico design of a multi-epitope vaccine against the tick-borne wetland virus.

Jul 2026 · Human Immunology · Vol 87 9, pp. 111805 · 0 citations · 70 references
Medicine

TL;DR

These computational results suggest that the construct has the potential to induce effective immunity against WELV, however further experimental validations in future have to be performed in order to confirm its efficacy against the pathogen.

Abstract

Background

The tick-borne viruses are primarily transmitted through the bites of infected ticks. Wetland virus (WELV) is a newly identified tick-borne pathogen with no licensed vaccines and limited preventive strategies.

Methods

In this study, a reverse vaccinology approach was used to design a multi-epitope vaccine using the conserved regions of key viral proteins of WELV.

Results

Multiple sequence alignment identified 51, 31, and 5 conserved regions in the RNA-dependent RNA polymerase (R), glycoprotein (G), and nucleocapsid (N) proteins, respectively. The epitope prediction across these regions identified 784 CTL, 933 HTL, and 123 B-cell epitopes, from which antigenic, non-allergenic, and non-toxic candidates were selected for vaccine construction. The final construct was predicted to have favourable antigenicity, solubility, and physicochemical properties. Structural analysis revealed that the construct has a high percentage of random coils (49.02%). Then, the tertiary structure was refined to improve its stereochemical quality, and in the refined structure 96.2% residues were in the most favoured regions. The conformational epitope prediction identified thirteen surface-accessible B-cell epitopes. Molecular docking analysis using HADDOCK showed possible interactions with multiple Toll-like receptors with predicted binding free energies ranging from -13.1 to -15.3 kcal/mol. Codon optimization and in silico cloning were performed to insert the construct into the pET-28a(+) vector. The immune simulation analysis predicted the possibility for inducing effective response, with antibody production, T-cell activation, and long-term immunological memory.

Conclusion

These computational results suggest that the construct has the potential to induce effective immunity against WELV, however further experimental validations in future have to be performed in order to confirm its efficacy against the pathogen.

View source

Similar papers

Open access Jul 2026

Design of a multi-epitope vaccine against Mycobacterium tuberculosis using reverse vaccinology and immunoreactive peptides

PE/PPE proteins and TCR-recognized immunoreactive peptides are suggested as promising vaccine components against tuberculosis and the designed MEV with the C-terminal fragment of CPE may represent a potential candidate for future development as a mucosal vaccine against M. tuberculosis.

N. Noori Goodarzi, Sepideh Fereshteh, Behzad Shahbazi et al. · 0 citations
Open access Aug 2026

In Silico design and evaluation of a multi-epitope vaccine candidate against Toxoplasma gondii for humans

The rationally designed multi-epitope vaccine demonstrates robust theoretical potential to elicit comprehensive, long-lasting immunity in humans, although its safety and effectiveness require additional experimental validation.

Chenchen Yi, Yu Shen, Ye Luo et al. · 0 citations
2026

Design of a Novel Multi-Epitope mRNA Vaccine against Marburg Virus using Reverse Vaccinology

Aim: The Marburg virus (MARV), a zoonotic pathogen, causes a severe hemorrhagic fever for which no approved vaccine currently exists. Methods: This study used reverse vaccinology to develop a multi-epitope vaccine against Marburg virus (MARV). To improve stability and translational efficiency, the construct was modified as an mRNA vaccine by adding a 5′ cap, 5′ UTR, Kozak sequence, tPA signal peptide, 3′ UTR, and poly(A) tail. Results: We selected the potential 06 CTL, 06 HTL, and 04 LBL epitopes with high antigenicity, no allergenicity, and no toxicity, and the epitopes were linked with the linkers (GPGPG, AAY, KK) and an adjuvant (β-defensin 2). The designed vaccine showed an antigenic score of 0.7189 with promising properties. Molecular docking reveals that the vaccine exhibits a strong binding affinity with human TLR4 (-1301.5 kcal/mol). Meanwhile, MD simulation confirms its structural stability, and immune simulations indicate robust cellular and humoral immune responses. Ultimately, in silico cloning validated the capacity for effective expression in E. coli. Finally, secondary structure revealed that the mRNA vaccine (-418.59 kcal/mol) was thermodynamically stable. These outcomes may contribute to the development of an experimental MARV vaccine. Conclusions: However, further experimental evaluation is necessary to assess the efficacy of the modified mRNA vaccine for MARV prevention.

Utsha Chowdhury, Al Mahmud, Md. Uddin et al. · 0 citations